Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877; SHA: 688180) announced that first patient dosing has been completed in the multi‑center, randomized, controlled, open‑label Phase III JS207‑017‑III‑HCC study (NCT07823348), evaluating JS207 in combination with JS007 versus toripalimab plus bevacizumab for the first‑line treatment of advanced hepatocellular carcinoma (HCC). The trial marks the first domestic registrational clinical study of JS207, the company’s self‑developed anti‑PD‑1/VEGF bispecific antibody.
Trial Initiation
| Item | Detail |
|---|---|
| Sponsor | Shanghai Junshi Biosciences (HKG: 1877; SHA: 688180) |
| Study Name / ID | JS207‑017‑III‑HCC (NCT07823348) |
| Design | Multi‑center, randomized, controlled, open‑label Phase III |
| Experimental Arm | JS207 (anti‑PD‑1/VEGF bispecific) + JS007 (anti‑CTLA‑4 mAb) |
| Control Arm | Toripalimab + bevacizumab |
| Indication | First‑line treatment of advanced hepatocellular carcinoma (HCC) |
| Key Milestone | First patient dosed – announced 30 Oct 2026 |
| Significance | First domestic registrational study of JS207 |
Drug Profile & Mechanism of Action
- JS207: A recombinant humanized anti‑PD‑1/VEGF bispecific antibody, self‑developed by Junshi Biosciences, combining the efficacy properties of immunotherapeutic drugs (PD‑1 checkpoint blockade) and anti‑angiogenic drugs (VEGF neutralization) in a single molecule – a dual mechanism designed to restore anti‑tumor immunity while normalizing tumor vasculature.
- JS007: A recombinant humanized anti‑CTLA‑4 monoclonal antibody injection, self‑developed by Junshi Biosciences, that specifically binds CTLA‑4 and blocks its interaction with ligand B7 (CD80 or CD86), thereby activating T lymphocytes and inhibiting tumor growth.
- Combination Rationale: Pairing a PD‑1/VEGF bispecific with an anti‑CTLA‑4 antibody targets complementary immune checkpoints plus angiogenesis – a multi‑axis strategy aimed at deeper and more durable responses in HCC, a highly vascular and immunosuppressive tumor type.
Clinical Evidence – Prior Phase II Results
| Endpoint | Result (JS207 + JS007) | Context |
|---|---|---|
| Objective Response Rate (ORR) | 44.1% | Among 34 efficacy‑evaluable patients |
| Disease Control Rate (DCR) | 85.3% | First‑line advanced HCC |
| 6‑Month PFS Rate | 67% | Progression‑free survival at 6 months |
| Safety | Well tolerated | Supported advancement to registrational Phase III |
The positive Phase II results of JS207 in combination with JS007 for first‑line treatment of advanced HCC formed the evidentiary basis for launching the pivotal Phase III head‑to‑head comparison against the established toripalimab + bevacizumab regimen.
Market Impact & Outlook
- Registrational Pathway Opened: As the first domestic registrational study of JS207, successful execution would position Junshi Biosciences to file for approval in first‑line advanced HCC – one of China’s highest‑incidence cancers with substantial unmet need.
- Head‑to‑Head Ambition: Benchmarking directly against toripalimab plus bevacizumab, an active standard‑of‑care combination, signals confidence that the JS207/JS007 regimen can match or surpass current first‑line therapy.
- Bispecific Platform Validation: JS207’s progression into pivotal development reinforces Junshi Biosciences’ bispecific antibody platform and its wholly self‑developed immuno‑oncology portfolio (JS207 + JS007, both proprietary assets).
- Competitive Landscape: The anti‑PD‑1/VEGF bispecific class is drawing global attention in solid tumors; early registrational movement in HCC strengthens Junshi Biosciences’ standing in a fast‑evolving race.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding clinical trial conduct, enrollment, regulatory review, and commercialization of JS207 and JS007. Actual results may differ materially due to risks including trial outcomes, safety findings, regulatory decisions, and competitive dynamics in the hepatocellular carcinoma treatment market. Phase II data are as reported by the company in a 34‑patient efficacy‑evaluable population; the Phase III study is ongoing.-Fineline Info & Tech
